1 PRODUCT NAME
CLINDATECH 10 mg/mL Topical Solution

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each mL of solution contains clindamycin hydrochloride equivalent to 10 mg of clindamycin.

Excipients with known effect:
Ethanol.
For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM
Topical solution.
A clear, hydroalcoholic solution.

4 CLINICAL PARTICULARS
4.1 Therapeutic indications
ClindaTech Topical Solution is indicated for the topical treatment of acne vulgaris particularly forms in which comedones, papules and pustules predominate.

4.2 Dose and method of administration
Topical.
ClindaTech Solution is for external use only and is applied directly to the skin.
Wash the entire face with, mild, non-alkaline soap and warm water prior to any application. Using the Dab-O-Matic applicator provided, apply a thin film directly to each acne lesion or to areas having potential of eruption.
ClindaTech Solution is usually applied to affected areas twice daily, once every morning and once at bedtime. The frequency of treatment will depend on the severity of acne condition as well as skin tolerance, but should not be more than twice daily.

Advice for monitoring
Treatment of acne vulgaris needs to be individualised according to the type of lesion predominate and the response of therapy. Application to the entire face of an average adult is equivalent to approximately 2mL of solution or clindamycin 20mg.
Generally, a decrease in the number of inflammatory lesions should be noticed after two or six weeks, but more than eight weeks of therapy may be required before any definite beneficial effects are observed. Therapy is usually continued until a satisfactory response is obtained. If condition does not seem to improve or worsens, modification of treatment or alternative therapy should be considered.
4.3 Contraindications
ClindaTech is contraindicated in patients with known history of hypersensitivity reactions to preparations containing clindamycin, lincomycin or other ingredients in the formulation (see section 6.1).

4.4 Special warnings and precautions for use

FOR EXTERNAL USE ONLY.

ClindaTech Solution is not indicated in severe and deep nodulo-cystic acne.

The drug should not be used for patients with a history of ulcerative colitis, regional enteritis or antibiotic-associated colitis.

Oral and parenteral clindamycin have been associated with severe diarrhoea and pseudomembranous colitis which may result inpatient death. Use of clindamycin hydrochloride topical solution results in absorption of the antibiotic from the skin surface. Diarrhoea, bloody diarrhoea and pseudomembranous colitis have been reported with the use of topical and systemic clindamycin.

It is important to consider the diagnosis of antibiotic associated colitis in patients who develop diarrhoea or colitis associated with antibiotic use. Antibiotic-associated colitis (whether pseudomembranous or not) appears to result from a toxin produced by Clostridium difficile in the alimentary canal. The severity of the colitis may range from mild watery diarrhoea to severe, persistent, life-threatening bloody diarrhoea. The diagnosis is usually made by recognition of the clinical symptoms. The symptoms may occur during therapy or up to several weeks after cessation of therapy. Additional confirmatory signs of antibiotic-associated colitis include pseudomembrane formation seen with colonoscopy, C. difficile culture from the stool, or assay of the stool for C. difficile toxin.

Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases appropriate therapy with a suitable oral antibacterial agent effective against C. difficile should be considered. Fluid, electrolytes and protein replacement should be provided when indicated.

Drugs which delay peristalsis, e.g. opiates and diphenoxylate with atropine (Lomotil) may prolong and/or worsen the condition and should not be used.

ClindaTech has an unpleasant taste. Caution should be exercised when applying the solution around the mouth to avoid any possible ingestion.

Avoid any contact with eyes, eyelids, abraded skin, nasal folds, lips or mucous membranes because of the irritating dryness caused by the alcoholic solvent. In the event of any accidental contact, bathe with copious amounts of cool water.

ClindaTech contains alcohol and may cause a burning sensation especially in those patients with sensitive skins. Sensitivity reactions including contact dermatitis and rash are rare but may occur in individuals who are hypertensive to clindamycin, lincomycin or any ingredient of the formulation.

Clindamycin should be prescribed with caution in atopic individuals or patients with impaired hepatic or renal functions. Safety has not been established when applied to areas affected concurrently with other dermatoses or to severely inflamed skin.
The use of clindamycin may cause overgrowth of non-susceptible organisms. Although rare, gram-negative folliculitis has been reported following topical application of clindamycin. If superinfection occurs, discontinue treatment.

Use of topical clindamycin has been associated with the development of strains of P. acnes resistant to clindamycin in some patients. If there is evidence of the development of clinical resistance during treatment, consideration should be given to discontinuation of treatment with ClindaTech.

4.5 Interaction with other medicines and other forms of interaction
Concurrent use of topical preparations containing alcohol (e.g. astringents, after shave lotion, medicated cosmetics) should be avoided because they potentiate the drying action on the skin. The solvent vehicles in some abrasive cleansers, medicated soaps or cosmetics are alcoholic. They may cause a cumulative irritant effect in patients undergoing treatment.

Topical acne preparations containing desquamative or abrasive agents (e.g. benzoyl peroxide, salicylic acid, resorcinol or tretinoin) may sensitise the skin to various local reactions. Concurrent use of these agents and topical clindamycin should be treated with caution in combination therapy. Concomitant use of other anti-acne or comedogenic cosmetic products should be avoided.

Both clindamycin and erythromycin appear to compete for the same ribosomal binding site in exerting their antibacterial action. Antagonism between the two anti-infective agents has been demonstrated. Concomitant use of either antibiotic in the topical treatment of acne is not recommended.

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the actions of other neuromuscular blocking agents.

Laboratory test interactions
No information is available about abnormal laboratory test results associated with the use of topical clindamycin in humans.

4.6 Fertility, pregnancy and lactation
Fertility
Reproductive studies have been performed in rats and mice using oral and parenteral doses up to 300 mg/kg/day and have revealed no evidence of harm to the foetus due to clindamycin. There are no adequate and well-controlled studies to demonstrate safe use in pregnant women.

Pregnancy
Category A.

Prescribing medicines in pregnancy Category A statement: Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed.

Lactation
It is not known if clindamycin is excreted in human milk following use of topically administered clindamycin. However, after oral or parenteral administration clindamycin has been detected in
human milk. In the absence of any adequate and well-controlled studies, topical clindamycin should
not be used in lactating women.

4.7 Effects on ability to drive and use machines
Clindamycin has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects
The most frequent adverse effect associated with the use of topical clindamycin solution is dryness
of skin. Other local reactions including erythema, peeling, oiliness, contact dermatitis, irritation,
itching and burning have been reported. While the exact proportion of patients reporting skin
reactions was not available in controlled clinical studies, these effects were generally mild and
most skin intolerance did not cause discontinuation of treatment.

Patients very frequently (>10%) experience a sensation of warmth, irritating, dryness and/or
burning experience following application of topical clindamycin, especially during the early phase
of treatment. Many of these reactions can be attributed to the dehydrating effect of the
hydralcoholic vehicle.

Diarrhoea is commonly reported (>1%, <10%), and infrequently, abdominal pain, bloody diarrhoea
(including pseudomembranous colitis) have also been reported following topical use of clindamycin
hydrochloride. In one multi-centre, double-blind and placebo-controlled study comparing two
formulations of 1% topical clindamycin in acne patients, it was noted that 6 of the 120 patients
(~5%) in the clindamycin hydrochloride group, 6 of the 124 patients (~5%) in the clindamycin
phosphate group and 2 of the 113 patients (~2%) in the placebo group reported diarrhoea during
the 8-week study. The diarrhoea episode in one clindamycin-treated patient was considered by the
investigator to be related to treatment. Sigmoidoscopy was performed and there was no evidence
of pseudomembranous colitis. The other patients with diarrhoea continued the study and
diarrhoea settled. No cause and effect relationship was established.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows
continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are
asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/

4.9 Overdose
No information is available concerning overdosage of topical clindamycin in humans.

For advice on the management of overdose please contact the National Poisons Centre on 0800
POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Microbiology
Clindamycin is a lincosamide antibiotic obtained as a semi-synthetic derivative from cultures of
Streptomyces lincolnis. It is active in vitro and in vivo against most gram-positive cocci and several
anaerobic and micro-aerophilic gram-negative and gram-positive organisms including
Propionibacterium acnes, a resident anaerobe found in acne-susceptible follicles.
Cross-resistance has been demonstrated between clindamycin and lincomycin. Antagonism has been demonstrated between clindamycin and erythromycin.

Clindamycin may be bactericidal in action, depending on the concentration of the drug attained at the site of infection and the susceptibility of the infecting organism. *In vitro* studies showed that the minimum inhibitory concentration of clindamycin against most wild strains of *P. acnes* (46 strains at the concentration of $10^8$/mL) ranged from 0.05 to 0.1 microgram/mL or below. The antibacterial action appears to relate to its ability in inhibiting ribosomal protein synthesis in susceptible organisms by binding to 50S ribosomal subunits.

The precise mechanism by which clindamycin reduces acne lesions has not been fully elucidated. Its therapeutic efficacy appears to act through its ability to decrease acne lesions, suppress or eliminate *P. acnes* in the sebaceous follicles, inhibit lipase activity, and reduce the levels of free fatty acids in skin surface lipids. Applied to the skin, clindamycin markedly reduces the follicular population of *P. acnes* and the concentration of skin surface free fatty acids.

### 5.2 Pharmacokinetic properties

Pharmacokinetic studies have not been undertaken with ClindaTech Topical Solution. Published results of studies which involved other clindamycin formulations are described below.

In an *in vitro* model using human skin, approximately 10% of the dose was absorbed into the stratum corneum following topical application of a 1% hydroalcoholic solution of radiolabelled clindamycin as the hydrochloride.

Absorption of clindamycin into comedones was assessed in an *in vitro* study in which comedones were removed from acne patients who had applied 1% clindamycin hydrochloride twice daily for 2 weeks or longer. The whole comedonal concentration of clindamycin ranged from 0-5 microgram of comedonal material with a mean concentration of 0.82 microgram/mg. It was stated that these antibiotic concentrations are above the minimum inhibitory concentration of clindamycin for most wild strains of *P. acnes* *in vitro* at 0.05-0.1 microgram/mL or below.

Systemic absorption of clindamycin was assessed by measurement of serum clindamycin in another open study of 18 acne patients. No clindamycin was detected in serum from any of the subjects obtained one to nine hours after application of a 1% clindamycin hydrochloride solution. The patients had been instructed to apply the solution with their fingertips to the affected areas 2 to 3 times daily. The duration of use ranged from 6-150 days with mean duration at 43.4 days, but the total volume of solution and surface area of application was not stated. The lower limit of quantification was 1 microgram/mL.

### 6 PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

- Ethanol
- Dioctyl malate
- Purified water

#### 6.2 Incompatibilities

Information on the physical or chemical compatibility of topical clindamycin with other topical preparations is not available.
6.3 Shelf life
2 years

6.4 Special precautions for storage
Store below 30°C.

6.5 Nature and contents of container
Bottle – white HDPE bottle containing 6 mL, 30 mL, 50 mL or 100 mL fitted with a screw-neck top and a Dab-O-matic applicator and a polypropylene closure.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling
Discard product three months after opening.

7 MEDICINE SCHEDULE
Prescription Medicine

8 SPONSOR
iNova Pharmaceuticals (New Zealand) Limited
c/- Simpson Grierson
88 Shortland Street,
Auckland 1141

9 DATE OF FIRST APPROVAL
9 November 2006

10 DATE OF REVISION OF THE TEXT
4 January 2018
### SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Date</th>
<th>Changes</th>
</tr>
</thead>
</table>
| 4 January 2018  | DS reformatted.  
Section 4.6: Pregnancy text changed from: Risk of use in pregnancy and class statement in reference to the Australian Categorisation System of Risk of Prescribing Medicines in Pregnancy. to “Prescribing medicines in pregnancy Category A statement: Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed.” Use in pregnancy categorisation unchanged. Corrected spelling of “parenteral”.  
Section 4.8 amended _ DS text replaced with Australian PI text. NZ DS text was a duplicate of Section 4.5.  
Section 5: added Pharmacotherapeutic group and ATC code  
Section 6.5: added “Not all pack sizes may be marketed.”  
Section 6.6: added: “Discard product three months after opening.” (from label)  
Section 8: Change in sponsor name & address to iNova |